Caris Life Sciences, Inc. (CAI) Financial Ratios
23 years of historical data (2003–2025) · Healthcare · Biotechnology
EV/EBITDA
70.87
↓-89% vs avg
5yr avg: 659.89
P/FCF
78.02
↓-88% vs avg
5yr avg: 674.37
P/B Ratio
53.49
↓-32% vs avg
5yr avg: 78.14
30Y Low78.1·High78.1
ROE
↓
-93.2%
↑-109% vs avg
5yr avg: -44.6%
30Y Low-93%·High47%
Debt/EBITDA
↓
5.60
↓-11% vs avg
5yr avg: 6.29
30Y Low1.7·High10.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CAI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Caris Life Sciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 78.0x P/FCF, 88% below the 5-year average of 674.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.2B | $45.1B | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $4.8B | $44.7B | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -9.72 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.43 | 55.55 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 53.49 | 78.14 | — | — | — | — | — | — | — | — | — |
| P/FCF | 78.02 | 674.37 | — | — | — | — | — | — | — | — | — |
| P/OCF | 62.76 | 542.51 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CAI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Caris Life Sciences, Inc.'s enterprise value stands at 70.9x EBITDA, 89% below its 5-year average of 659.9x. The Healthcare sector median is 14.2x, placing the stock at a 399% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 55.04 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | 70.87 | 659.89 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 106.40 | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 668.11 | — | — | — | — | — | — | — | — | — |
CAI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Caris Life Sciences, Inc. earns an operating margin of 5.6%. Operating margins have expanded from -104.4% to 5.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -93.2% indicates the company is currently destroying shareholder equity. ROIC of 21.3% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.4% | 66.4% | 43.4% | 29.2% | 31.0% | 62.6% | 48.1% | 49.4% | 48.6% | 46.7% | 50.4% |
| Operating Margin | 5.6% | 5.6% | -62.4% | -104.4% | -122.2% | 47.3% | 31.3% | 34.4% | 30.3% | 22.4% | 27.3% |
| Net Profit Margin | -66.2% | -66.2% | -68.4% | -111.5% | -124.1% | 9.4% | 7.4% | 18.2% | 20.7% | 2.0% | 10.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -93.2% | -93.2% | — | — | — | 4.0% | 4.4% | 12.4% | 14.1% | 1.3% | 5.9% |
| ROA | -73.2% | -73.2% | -74.5% | -60.4% | -19.3% | 1.0% | 1.0% | 2.9% | 3.2% | 0.3% | 1.4% |
| ROIC | 21.3% | 21.3% | — | — | -55.3% | 4.1% | 3.5% | 4.4% | 3.8% | 2.7% | 2.9% |
| ROCE | 7.7% | 7.7% | -103.7% | -71.1% | -22.0% | 5.7% | 5.0% | 6.3% | 5.2% | 3.6% | 4.1% |
CAI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Caris Life Sciences, Inc. carries a Debt/EBITDA ratio of 5.6x, which is highly leveraged (74% above the sector average of 3.2x). The company holds a net cash position — cash of $798M exceeds total debt of $379M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.66 | 0.66 | — | — | — | 2.49 | 3.03 | 3.08 | 3.02 | 3.23 | 3.11 |
| Debt / EBITDA | 5.60 | 5.60 | — | — | — | 6.99 | 8.59 | 7.93 | 7.78 | 8.55 | 7.85 |
| Net Debt / Equity | — | -0.73 | — | — | — | 2.41 | 2.96 | 3.01 | 2.96 | 3.13 | — |
| Net Debt / EBITDA | -6.18 | -6.18 | — | — | — | 6.78 | 8.40 | 7.76 | 7.62 | 8.28 | 7.56 |
| Debt / FCF | — | -6.26 | — | — | — | 29.40 | — | — | — | — | — |
| Interest Coverage | -0.20 | -0.20 | -4.63 | -9.80 | -11.03 | 2.34 | 1.70 | 2.04 | 2.08 | 1.23 | 1.87 |
Net cash position: cash ($798M) exceeds total debt ($379M)
CAI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Caris Life Sciences, Inc.'s current ratio of 7.85x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.55x to 7.85x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.85 | 7.85 | 1.30 | 2.55 | 3.77 | 0.67 | 1.74 | 0.52 | 0.54 | 0.82 | 0.66 |
| Quick Ratio | 7.85 | 7.85 | 1.06 | 2.04 | 3.43 | 0.67 | 1.74 | 0.52 | 0.54 | 0.82 | 0.66 |
| Cash Ratio | 6.29 | 6.29 | 0.40 | 1.28 | 2.99 | 0.41 | 0.16 | 0.29 | 0.25 | 0.40 | 0.34 |
| Asset Turnover | — | 0.72 | 1.20 | 0.74 | 0.36 | 0.11 | 0.14 | 0.14 | 0.14 | 0.14 | 0.13 |
| Inventory Turnover | — | — | 5.90 | 4.43 | 3.80 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 50.41 | 78.13 | 65.93 | 56.80 | 179.14 | 139.92 | 145.22 | 105.46 | 103.79 | 111.75 |
CAI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Caris Life Sciences, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | 63.8% | 28.5% | 4.1% | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.3% | 0.1% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $1.7B | $255M | $255M | $255M | $18M | $18M | $20M | $20M | $19M | $21M |
Peer Comparison
Compare CAI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CAIYou | $5B | -9.7 | 70.9 | 78.0 | 66.4% | 5.6% | -93.2% | 21.3% | 5.6 |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 NTRA | $33B | -152.2 | — | 303.7 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 GH | $17B | -39.7 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 FDMT | $505M | -4.0 | — | — | 91.1% | -187.2% | -27.6% | -28.1% | — |
 CDNA | $1B | -65.5 | — | 37.4 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 PACB | $435M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 CERT | $862M | -554.0 | 8.8 | 9.1 | 61.5% | 5.0% | -0.2% | 1.5% | 0.1 |
 ACMR | $7B | 80.2 | 54.2 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CAI — Frequently Asked Questions
Quick answers to the most common questions about buying CAI stock.
What is Caris Life Sciences, Inc.'s P/E ratio?
Caris Life Sciences, Inc.'s current P/E ratio is -9.7x. This places it at the 50th percentile of its historical range.
What is Caris Life Sciences, Inc.'s EV/EBITDA?
Caris Life Sciences, Inc.'s current EV/EBITDA is 70.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is Caris Life Sciences, Inc.'s ROE?
Caris Life Sciences, Inc.'s return on equity (ROE) is -93.2%. The historical average is 7.4%.
Is CAI stock overvalued?
Based on historical data, Caris Life Sciences, Inc. is trading at a P/E of -9.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Caris Life Sciences, Inc.'s profit margins?
Caris Life Sciences, Inc. has 66.4% gross margin and 5.6% operating margin.
How much debt does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc.'s Debt/EBITDA ratio is 5.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.